Chimeric anti-tnf-α monoclonal antibody ca2 binds recombinant transmembrane tnf-α and activates immune effector functions

Cytokine

Volumn 7, Issue 3, 1995, Pages 251-259

  Scallon, Bernard J ^a   Moore, Maria Arevalo ^a   Trinh, Han ^a   Knight, David M ^a   Ghrayeb, John ^a  

^a CENTOCOR INC   (United States)

Author keywords

Anti TNF ; Antibody dependent cellular cytotoxicity; Complement dependent cytoxicity; Transmembrane TNF

Indexed keywords

EID: 0029004771     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1995.0029     Document Type: Article

References (42)

1. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M (1989) Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. The Lancet ii:244-247.
2. Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, Sato K, Shimizu M, Maini R, Feldmann M, Kishimoto T (1988) Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 18:1797-1801.
3. Alvaro-Gracia JM, Zvaifler NJ, Brown CB, Kaushansky K, Firestein GS (1991) Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by Il-1 and tumor necrosis factoralpha. J Immunol 146:3365-3371.
4. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M (1991) Expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) in rheumatoid arthritis: regulation by tumor necrosis factor-α. Eur J Immunol 21:2575-2579.
5. Brennan FM, Zachariae COC, Chantry D, Larsen CG, Turner M, Maini RN, Matsushima K, Feldmann M (1990) Detection of interleukin-8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of IL-8 mRNA by isolated synovial cells. Eur J Immunol 20:2141-2144.
6. Aggarwal BB, Vilcek J (1992) Tumour Necrosis Factors: Structure, Function, and Mechanism of Action. Marcel Dekker, Inc., New York.
7. Beutler B (1992) Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine. Raven Press, New York.
8. Fiers W (1991) Tumor necrosis factor: characterization at the molecular, cellular and in vivo level. FEBS Letters 285:199-212.
9. Beutler B, Cerami A (1989) The biology of cachectin/TNF-a primary mediator of the host response. Ann Rev Immunol 7:625-655.
10. Williams RO, Mason LJ, Feldmann M, Maini RN (1994) Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. Proc Natl Acad Sci USA 91:2762-2766.
11. Wooley PH, Dutcher J, Widmer MB, Gillis S (1993) Influence of a recombinant human soluble tumor necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 151:6602-6607.
12. Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci 89:9784-9788.
13. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548-1561.
14. Ashkenazi A, Marsters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, Goeddel DV, Palladino MA, Smith DH (1991) Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci 88:10535-10539.
15. Lesslauer W, Tabuchi H, Gentz R, Brockhaus M, Schlaeger DJ, Grau G, Piguet PF, Pointaire P, Vassalli P, Loetscher H (1991) Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 21:2883-2886.
16. Silva AT, Bayston KF, Cohen J (1990) Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-alpha in experimental gram negative shock. J Infect Dis 162:421-427.
17. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662-664.
18. Baker D, Butler D, Scallon BJ, O’Neill JK, Turk JL, Feldmann M (1994) Control of established experimental allergic encephalomyelitis by inhibition of tumour necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur J Immunol 24:2040-2048.
19. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody J (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthr Rheum 36:1681-1690.
20. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smollen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α versus placebo in rheumatoid arthritis. The Lancet 344:1105-1110.
21. Kriegler M, Perez C, DeFay K, Albert I, Lu SD (1988) A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53:45-53.
22. Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M (1990) A nonsecre table cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63:251-258.
23. + T cell clones provides a costimulatory signal for human B cell activation. J Exp Med 177:1575-1585.
24. Macchia D, Almerigogna F, Parronchi P, Ravina A, Maggi E, Romagnani S (1993) Membrane tumor necrosis factor-α is involved in the polyclonal B-cell activation induced by HIV-infected human T cells. Nature 363:464-466.
25. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A (1992) A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci 89:6550-6554.
26. Lane P, Traunecker A, Hubele S, Inui S, Lanzavecchia A, Gray D (1992) Activated human T cells express a ligand for the human B cell associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes. Eur J Immunol 22:2573-2578.
27. Janossy G, Panayi G, Duke O, Bofill M, Poulter LW, Goldstein G (1981) Rheumatoid arthritis: a disease of T lymphocyte/macrophage immunoregulation. Lancet ii:839-841.
28. Klareskog L, Forsum U, Scheynius A, Kabelitz D, Wigzell H (1982) Evidence in support of a self perpetuating HLA-DR dependent delayed type cell reaction in rheumatoid arthritis. Proc Natl Acad Sci USA 72:3632-3636.
29. Chu CQ, Field M, Feldmann M, Maini RN (1991) Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthr Rheum 34:1125-1132.
30. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Arevalo Moore M, Vilcek J, Daddona P, Ghrayeb J (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30:1443-1453.
31. Siegel SA, Shealy DJ, Nakada MT, Le J, Woulfe DS, Probert L, Kollias G, Ghrayeb J, Vilček J, Daddona PE (1995) The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 7:15-25.
32. Duncan AR, Winter G (1988) The binding site for C1q on IgG. Nature 332:738-740.
33. Oi VT, Vuong TM, Hardy R, Reidler J, Dangl J, Herzenberg LA, Stryer L (1984) Correlation between segmental flexibility and effector function of antibodies. Nature 307:136-140.
34. Dangl JL, Wensel TG, Morrison SL, Stryer L, Herzenberg LA, Oi VT (1988) Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies. EMBO J 7:1989-1994.
35. Horgan C, Brown K, Pincus SH (1993) Studies on antigen binding by intact and hinge-deleted chimeric antibodies. J Immunol 150:5400-5407.
36. Morelock MM, Rothlein R, Bright SM, Robinson MK, Graham ET, Sabo JP, Owens R, King DJ, Norris SH, Scher DS, Wright JL, Adair JR (1994) Isotype choice for chimeric antibodies affects binding properties. J Biol Chem 269:13048-13055.
37. Suitters AJ, Foulkes R, Opal SM, Palardy JE, Emtage JS, Rolfe M, Stephens S, Morgan A, Holt AR, Chaplin LC, Shaw NE, Nesbitt AM, Bodmer MW (1994) Differential effect of isotype on efficacy of anti-tumor necrosis factor a chimeric antibodies in experimental septic shock. J Exp Med 179:849-856.
38. Yamagishi J, Kawashima H, Matsuo N, Ohue M, Yamayoshi M, Fukui T, Kotani H, Furuta R, Nakano K, Yamada M (1990) Mutational analysis of structure-activity relationships in human tumour necrosis factor-alpha. Prot Eng 3:713-719.
39. Marmenout A, Fransen L, Tavernier J, Van’d HJ, Tizard R, Kawashima E, Shaw A, Johnson MJ, Semon D, Muller R, Ruysschaert M-R, Van Vliet A, Fiers W (1985) Molecular cloning and expression of human tumor necrosis factor and comparison with mouse tumour necrosis factor. Eur J Biochem 152:515-519.
40. Foecking MK, Hofstetter H (1985) Powerful and versatile enhancer-promoter unit for mammalian expression vectors. Gene 45:101-105.
41. Scatchard G (1949) The attractions of proteins for small molecules and ions. Ann NY Acac Sci 51:660-672.
42. Tonnesen MG, Anderson DC, Springer TA, Knedler A, Avdi N, Henson PM (1989) Adherence of neutrophils to cultured human microvascular endothelial cells. J Clin Invest 83:637-646.